
|Articles|October 19, 2016 (Updated: November 11, 2020)
Transplant May Still Benefit CML Patients Experiencing TKI Resistance
Author(s)Bobby Lazzara, MD
When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
Advertisement
The need for allogeneic stem cell transplant in chronic myeloid leukemia (CML) patients has decreased due to tyrosine kinase inhibitor (TKI) use. But when CML patients develop resistance or intolerance to these drugs, transplant may be the only option.
This study was recently
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement





Examining TRX103 Tolerance Against Transient Suppression in Mismatched HCT
Published: | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC
2
Lessons From the Withdrawal of Atezolizumab in Metastatic TNBC
3
Molecular Interception: Discussing the Future of Surgery in Breast Cancer
4
Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer
5















































